Acusphere (OTCMKTS:ACUS) & Metagenomi (NASDAQ:MGX) Financial Analysis

Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Acusphere and Metagenomi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acusphere	0	0	0	0	0.00
Metagenomi	1	0	3	1	2.80

Metagenomi has a consensus target price of $10.00, indicating a potential upside of 557.89%. Given Metagenomi’s stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Acusphere.

Risk and Volatility

Acusphere has a beta of -2.23, suggesting that its stock price is 323% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

Valuation and Earnings

This table compares Acusphere and Metagenomi”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acusphere	N/A	N/A	N/A	N/A	N/A
Metagenomi	$30.91 million	1.85	-$78.06 million	($2.40)	-0.63

Acusphere has higher earnings, but lower revenue than Metagenomi.

Profitability

This table compares Acusphere and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acusphere	N/A	N/A	N/A
Metagenomi	-287.06%	-43.19%	-31.06%

Summary

Metagenomi beats Acusphere on 6 of the 9 factors compared between the two stocks.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.